1808 related articles for article (PubMed ID: 16472106)
1. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
2. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
Masimirembwa CM; Bredberg U; Andersson TB
Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
[TBL] [Abstract][Full Text] [Related]
3. Human hepatic cell cultures: in vitro and in vivo drug metabolism.
Gómez-Lechón MJ; Donato T; Ponsoda X; Castell JV
Altern Lab Anim; 2003; 31(3):257-65. PubMed ID: 15612868
[TBL] [Abstract][Full Text] [Related]
4. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
Yan Z; Caldwell GW
Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
[TBL] [Abstract][Full Text] [Related]
5. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
6. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
7. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
9. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.
Shaffer CL; Scialis RJ; Rong H; Obach RS
Biopharm Drug Dispos; 2012 Mar; 33(2):72-84. PubMed ID: 22213407
[TBL] [Abstract][Full Text] [Related]
10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
11. CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
Lin JH
Pharm Res; 2006 Jun; 23(6):1089-116. PubMed ID: 16718615
[TBL] [Abstract][Full Text] [Related]
12. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays.
Wu X; Wang J; Tan L; Bui J; Gjerstad E; McMillan K; Zhang W
J Biomol Screen; 2012 Jul; 17(6):761-72. PubMed ID: 22460176
[TBL] [Abstract][Full Text] [Related]
13. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
14. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
[TBL] [Abstract][Full Text] [Related]
15. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
[TBL] [Abstract][Full Text] [Related]
16. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
17. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery.
Masimirembwa CM; Thompson R; Andersson TB
Comb Chem High Throughput Screen; 2001 May; 4(3):245-63. PubMed ID: 11375740
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling for ADME.
Guner OF; Bowen JP
Curr Top Med Chem; 2013; 13(11):1327-42. PubMed ID: 23675939
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
Reichel A; Lienau P
Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
[TBL] [Abstract][Full Text] [Related]
20. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]